Literature DB >> 9071932

Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration.

M A Hull1, A Knifton, B Filipowicz, J L Brough, G Vautier, C J Hawkey.   

Abstract

BACKGROUND: Acid stable basic fibroblast growth factor (bFGF) promotes angiogenesis and healing of gastric ulcers in rats and reduces subsequent non-steroidal anti-inflammatory drug (NSAID) induced relapse. AIMS: To test in a double blind, placebo controlled, three way crossover study whether bFGF promotes healing and reduces subsequent relapse in a human model of gastric ulceration.
SUBJECTS: Twelve healthy volunteers.
METHODS: Subjects took aspirin 900 mg twice daily (days 1-3) with bFGF 0.1 mg twice daily or cimetidine 400 mg twice daily or placebo (days 1-14) and then indomethacin 50 mg thrice daily (days 15-21). Endoscopy was performed on days 1, 4, 8, 15, and 22 during each treatment period. Eight antral biopsy specimens were taken on day 1 and the number of unhealed biopsy induced mini-ulcers and NSAID induced erosions counted during subsequent endoscopies.
RESULTS: Basic FGF and cimetidine were protective against aspirin and indomethacin induced duodenal (but not gastric) injury compared with placebo. There was significant relapse of biopsy induced mini-ulcers after indomethacin only in the placebo group (0 (0-0) before v 1 (0-4.5) after; p > 0.05). TGP-580 was detected in serum of one volunteer.
CONCLUSIONS: Healing with bFGF (and cimetidine) was associated with reduced NSAID induced ulcer relapse in this model of gastric ulceration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9071932      PMCID: PMC1027049          DOI: 10.1136/gut.40.2.204

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  bFGF induces its own gene expression in astrocytic and hippocampal cell cultures.

Authors:  B Flott-Rahmel; W Gerdes; P A Pechan; W Brysch; K H Schlingensiepen; W Seifert
Journal:  Neuroreport       Date:  1992-12       Impact factor: 1.837

2.  Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial.

Authors:  D Y Graham; N M Agrawal; S H Roth
Journal:  Lancet       Date:  1988-12-03       Impact factor: 79.321

3.  Use of microbleeding and an ultrathin endoscope to assess gastric mucosal protection by famotidine.

Authors:  T K Daneshmend; P J Prichard; N K Bhaskar; P J Millns; C J Hawkey
Journal:  Gastroenterology       Date:  1989-10       Impact factor: 22.682

4.  The Veterans Administration Cooperative Study on Gastric Ulcer. 4. The follow-up period.

Authors:  D H Hanscom; E Buchman
Journal:  Gastroenterology       Date:  1971-10       Impact factor: 22.682

Review 5.  A review of the therapeutic efficacy of misoprostol, a prostaglandin E1 analogue.

Authors:  P A Nicholson
Journal:  S Afr Med J       Date:  1988-07-02

6.  Interobserver variation in assessment of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs.

Authors:  N Hudson; S Everitt; C J Hawkey
Journal:  Gut       Date:  1994-08       Impact factor: 23.059

Review 7.  Cimetidine: an immunomodulator.

Authors:  A Kumar
Journal:  DICP       Date:  1990-03

8.  Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal anti-inflammatory drugs.

Authors:  N Hudson; M Balsitis; S Everitt; C J Hawkey
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

9.  Indomethacin and turnover of gastric mucosal cells in the rat.

Authors:  A Baumgartner; H R Koelz; F Halter
Journal:  Am J Physiol       Date:  1986-06

10.  Antacid provides better restoration of glandular structures within the gastric ulcer scar than omeprazole.

Authors:  A Schmassmann; A Tarnawski; H A Gerber; B Flogerzi; M Sanner; L Varga; F Halter
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

View more
  3 in total

Review 1.  Fibroblast growth factors, old kids on the new block.

Authors:  Xiaokun Li; Cong Wang; Jian Xiao; Wallace L McKeehan; Fen Wang
Journal:  Semin Cell Dev Biol       Date:  2016-01-06       Impact factor: 7.727

2.  Similarity of recombinant human perlecan domain 1 by alternative expression systems bioactive heterogenous recombinant human perlecan D1.

Authors:  April L Ellis; Wensheng Pan; Guang Yang; Kim Jones; Christine Chuang; John M Whitelock; Arthur A DeCarlo
Journal:  BMC Biotechnol       Date:  2010-09-09       Impact factor: 2.563

3.  Mast cells are critical for protection against peptic ulcers induced by the NSAID piroxicam.

Authors:  Daniel D Hampton; Laura P Hale
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.